<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855660</url>
  </required_header>
  <id_info>
    <org_study_id>13790</org_study_id>
    <secondary_id>2008-005569-70</secondary_id>
    <nct_id>NCT00855660</nct_id>
  </id_info>
  <brief_title>Effect of Riociguat on Bone Metabolism</brief_title>
  <official_title>Investigation of the Effect of Riociguat, Administered as 2.5 mg IR-tablets TID Over 14 Days, on Bone Metabolism in a Randomized, Placebo-controlled, Double-blind, 2-fold Cross-over Design in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days,
      on bone metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical pharmacology
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary excretion (over 24 hours) of C-terminal cross-linking telopeptides of type I collagen (CTX)</measure>
    <time_frame>From Day -01 to 16</time_frame>
    <description>Marker of bone resorption</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-7)</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 0</time_frame>
    <description>Area under the plasma concentration vs time curve (AUC) from zero to 7 hours after single (first) dose for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-7)ss</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 13</time_frame>
    <description>AUC(0-7) at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 0</time_frame>
    <description>Maximum drug concentration in plasma after single dose administration for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 13</time_frame>
    <description>Maximum drug concentration in plasma at steady state during a dosage interval for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>On Days 03 and 08</time_frame>
    <description>Drug concentration in plasma at expected time of minimum (trough) concentration for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-7)norm</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 0</time_frame>
    <description>AUC(0-7) divided by dose per kg body weight for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-7)ss,norm</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 13</time_frame>
    <description>AUC(0-7)ss divided by dose per kg body weight for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,norm</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 0</time_frame>
    <description>Maximum drug concentration in plasma after (first) single dose administration divided by dose (mg) per kg body weight for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss,norm</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 13</time_frame>
    <description>Maximum drug concentration in plasma at steady state during a dosage interval divided by dose (mg) per kg body weight for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 0</time_frame>
    <description>Time to reach maximum drug concentration in plasma after single (first) dose for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose on Day 13</time_frame>
    <description>tmax at steady state for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aeur(0-7)</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose</time_frame>
    <description>Amount of drug excreted via urine from zero to 7 hours after administration for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Aeur(0-7)</measure>
    <time_frame>Pre-dose and up to 7 hours post-dose</time_frame>
    <description>Aeur(0-7) expressed as percent of dose administered for riociguat and its metabolite M-1 (BAY60-4552)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion (over 24 hours) of N-terminal cross-linking telopeptides of type I collagen (NTX)</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Marker of bone resorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Marker of bone resorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum N-terminal propeptide of type I collagen (PINP)</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Marker of bone formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bone-specific alkaline phosphatase (bAP)</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Marker of bone formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin, protein</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of albumin, protein in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclic guanosine monophosphate (cGMP)</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of cGMP in plasma and urinary excretion (over 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, sodium, potassium</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of calcium, sodium, potassium in serum and urinary excretion (over 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Volume of urine excreted (over 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of plasma renin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>For estimation of glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum osteocalcin</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of osteocalcin in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of creatinine in serum and urinary excretion (over 24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of phosphate in serum only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone (PTH)</measure>
    <time_frame>From -01 to 16 Days</time_frame>
    <description>Determination of PTH in serum only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <arm_group>
    <arm_group_label>Riociguat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg</intervention_name>
    <description>Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.</description>
    <arm_group_label>Riociguat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as a single tablet, thrice daily, over 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male white subjects

          -  18 to 45 years of age

          -  BMI between 18 and 28 kg/m2

          -  Subjects who are able to understand and follow instructions and who are able to
             participate in the study for the entire period

        Exclusion Criteria:

          -  Relevant deviation from the normal range in the clinical examination; in clinical
             chemistry, hematology, or urinalysis

          -  Resting heart rate in the awake subject below 45 BPM or above 90 BPM

          -  Systolic blood pressure below 100 mmHg or above 145 mmHg

          -  Diastolic blood pressure above 95 mmHg

          -  Relevant pathological changes in the ECG such as a second or third-degree AV block,
             prolongation of the QRS complex over 120 msec or of the QT / QTc-interval over 450
             msec for males

          -  History of genetic muscle or bone disease of any kind

          -  Completely sedentary or extremely fit subjects

          -  Fractures in the preceding 12 months

          -  Psychiatric diseases

          -  History of peptic ulcers or relevant gastro-esophageal reflux disease

          -  Subjects with hypersensitivity to the investigational drug riociguat or ranitidine, or
             to inactive constituents

          -  Regular daily consumption of more than half a liter of usual beer or the equivalent
             quantity of approximately 20 g of alcohol in another form, more than 1 L of
             xanthine-containing beverages, recent smoking history

          -  Use of medication within the 2 weeks preceding the study which could have interfered
             with the investigational drug riociguat or ranitidine

          -  Subjects with a medical disorder, condition or history of such that would have
             impaired the subject's ability to participate or complete this study in the opinion of
             the investigator or the sponsor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Metabolism</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

